For instance, Raison and colleagues reported that infliximab, a tumor necrosis factor (TNF) antagonist, ameliorates depressive symptoms in a subpopulation of MDD patients who have high level of C-reactive protein (CRP) in plasma, but not in those with low levels of CRP (6). Here, CRP is linked to major depressive disorder.